Adiponectin as a regulator of vascular redox state: Therapeutic implications

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 2, 2011, Pages 78-88

  Antonopoulos, Alexios S ^a   Lee, Regent ^a   Margaritis, Marios ^a   Antoniades, Charalambos ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adiponectin; Adipose tissue; Atherosclerosis; Endothelium; Treatment; Vascular redox

Indexed keywords

ADIPONECTIN; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMBLICA OFFICINALIS EXTRACT; ENALAPRIL; EZETIMIBE; FOLIC ACID; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; IMIDAPRIL; LOSARTAN; NEBIVOLOL; NICOTINIC ACID; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; RIMONABANT; ROSUVASTATIN; SIBUTRAMINE; SIMVASTATIN; STATIN; SULFONYLUREA; TETRAHYDROBIOPTERIN;

BIOAVAILABILITY; BIOSYNTHESIS; CARDIOVASCULAR RISK; CELL FUNCTION; EMBLICA OFFICINALIS; HEART FAILURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UNSPECIFIED SIDE EFFECT; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ADIPOKINES; ADIPONECTIN; ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; OBESITY; OXIDATION-REDUCTION; PATENTS AS TOPIC; VASCULAR DISEASES;

EID: 79959360734     PISSN: 15748901     EISSN: 15748901     Source Type: Journal    
DOI: 10.2174/157489011795933837     Document Type: Review

References (163)

1. Verhagen SN, Visseren FL. Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 2011; 214: 3-10.
2. Ashwin PJ, Dilipbhai PJ. Leptin and the cardiovascular system: A review. Recent Pat Cardiovasc Drug Discov 2007; 2: 100-9.
3. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: From obesity to cardiovascular disease. Obes Rev 2009; 10: 269-79.
4. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.
5. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6.
6. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-8.
7. Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways. FEBS Lett 2010; 584: 4280-6.
8. Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, et al. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs RD 2006; 7: 99-110.
9. Tian F, Luo R, Zhao Z, Wu Y, Ban D. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes 2010; 118: 258-65.
10. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010; 209: 89-95.
11. Merchant N, Rahman ST, Ferdinand KC, Haque T, Umpierrez GE, Khan BV. Effects of nebivolol in obese African Americans with hypertension (NOAAH): Markers of inflammation and obesity in response to exercise-induced stress. J Hum Hypertens 2010.
12. Metais C, Forcheron F, Abdallah P, Basset A, Del Carmine P, Bricca G, et al. Adiponectin receptors: Expression in Zucker diabetic rats and effects of fenofibrate and metformin. Metabolism 2008; 57: 946-53.
13. Landrier JF, Gouranton E, El Yazidi C, Malezet C, Balaguer P, Borel P, et al. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology 2009; 150: 5318-25.
14. Antonopoulos AS, Antoniades C, Tousoulis D, Bakogiannis C, Demosthenous M, Psarros C, et al. Novel therapeutic strategies targeting vascular redox in human atherosclerosis. Recent Pat Cardiovasc Drug Discov 2009; 4: 76-87.
15. Inagi R. Oxidative stress in cardiovascular disease: A new avenue toward future therapeutic approaches. Recent Pat Cardiovasc Drug Discov 2006; 1: 151-9.
16. Viljoen A. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Pat Cardiovasc Drug Discov 2008; 3: 84-91.
17. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-201.
18. Antoniades C, Antonopoulos AS, Bendall JK, Channon KM. Targeting redox signaling in the vascular wall: From basic science to clinical practice. Curr Pharm Des 2009; 15: 329-42.
19. Antoniades C, Shirodaria C, Leeson P, Antonopoulos A, Warrick N, Van-Assche T, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009; 30: 1142-50.
20. Tousoulis D, Antoniades C, Tentolouris C, Goumas G, Stefanadis C, Toutouzas P. L-arginine in cardiovascular disease: Dream or reality? Vasc Med 2002; 7: 203-11.
21. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: Relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002; 53: 515-24.
22. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004; 109: II27-33.
23. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007; 116: 2851-9.
24. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656-62.
25. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: Specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-97.
26. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, et al. Systemic regulation of vascular NAD(P)H oxidase activity and NOX isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 2004; 24: 1614-20.
27. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010; 122: S66-73.
28. Shah AM, Channon KM. Free radicals and redox signalling in cardiovascular disease. Heart 2004; 90: 486-7.
29. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-66.
30. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313-25.
31. Korner A, Wabitsch M, Seidel B, Fischer-Posovszky P, Berthold A, Stumvoll M, et al. Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 2005; 337: 540-50.
32. Delaigle AM, Jonas JC, Bauche IB, Cornu O, Brichard SM. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 2004; 145: 5589-97.
33. Das K, Lin Y, Widen E, Zhang Y, Scherer PE. Chromosomal localization, expression pattern, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem Biophys Res Commun 2001; 280: 1120-9.
34. Park SK, Oh SY, Lee MY, Yoon S, Kim KS, Kim JW. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes 2004; 53: 2757-66.
35. Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, et al. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 2005; 54: 1744-54.
36. Seo JB, Moon HM, Noh MJ, Lee YS, Jeong HW, Yoo EJ, et al. Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem 2004; 279: 22108-17.
37. Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006; 339: 624-32.
38. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 142-6.
39. Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y. c-Jun Nterminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2005; 327: 460-7.
40. Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006; 188: 231-44.
41. Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB. Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am J Clin Nutr 2006; 84: 328-35.
42. Tsukinoki R, Morimoto K, Nakayama K. Association between lifestyle factors and plasma adiponectin levels in Japanese men. Lipids Health Dis 2005; 4: 27.
43. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009; 53: 2070-7.
44. Buechler C, Schaffler A, Johann M, Neumeier M, Kohl P, Weiss T, et al. Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol 2009; 24: 558-63.
45. Choi KC, Lee SY, Yoo HJ, Ryu OH, Lee KW, Kim SM, et al. Effect of PPAR-delta agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. Biochem Biophys Res Commun 2007; 357: 62-7.
46. Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, et al. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: Lessons from the high fructose fed rat model. Am J Hypertens 2007; 20: 206-10.
47. Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2006; 1: 193-209.
48. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: A 3-year weight loss study. Eur J Endocrinol 2008; 158: 179-87.
49. Fujikawa R, Ito C, Nakashima R, Orita Y, Ohashi N. Is there any association between subcutaneous adipose tissue area and plasma total and high molecular weight adiponectin levels? Metabolism 2008; 57: 506-10.
50. Bluher M, Williams CJ, Kloting N, Hsi A, Ruschke K, Oberbach A, et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007; 30: 3110-5.
51. Farvid MS, Ng TW, Chan DC, Barrett PH, Watts GF. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 2005; 7: 406-13.
52. Frederiksen L, Nielsen TL, Wraae K, Hagen C, Frystyk J, Flyvbjerg A, et al. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab 2009; 94: 4010-5.
53. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1[agr] and mitochondria by Ca2+ and AMPK/SIRT1. Nature 464: 1313-9.
54. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17: 55-63.
55. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 2010; 120: 4342-52.
56. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
57. Bruce CR, Mertz VA, Heigenhauser GJ, Dyck DJ. The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes 2005; 54: 3154-60.
58. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-69.
59. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52: 239-43.
60. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
61. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-81.
62. Dietze-Schroeder D, Sell H, Uhlig M, Koenen M, Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005; 54: 2003-11.
63. Brown JE, Conner AC, Digby JE, Ward KL, Ramanjaneya M, Randeva HS, et al. Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin. Peptides 2010; 31: 944-9.
64. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290: 1084-9.
65. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, et al. Elevated serum concentration of adiposederived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 2002; 25: 1665-6.
66. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-8.
67. Xi W, Satoh H, Kase H, Suzuki K, Hattori Y. Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: Vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 2005; 332: 200-5.
68. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46: 1543-9.
69. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-6.
70. Cao Y, Tao L, Yuan Y, Jiao X, Lau WB, Wang Y, et al. Endothelial dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell Cardiol 2009; 46: 413-9.
71. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-301.
72. Kim JE, Song SE, Kim YW, Kim JY, Park SC, Park YK, et al. Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol 2010; 207: 35-44.
73. Chang J, Li Y, Huang Y, Lam KS, Hoo RL, Wong WT, et al. Adiponectin prevents diabetic premature senescence of endothelial progenitor cells and promotes endothelial repair by suppressing the p38 MAP kinase/p16INK4A signaling pathway. Diabetes 2010; 59: 2949-59.
74. Magalang UJ, Rajappan R, Hunter MG, Kutala VK, Kuppusamy P, Wewers MD, et al. Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 2006; 8: 2179-86.
75. Akifusa S, Kamio N, Shimazaki Y, Yamaguchi N, Yamashita Y. Regulation of globular adiponectin-induced apoptosis by reactive oxygen/nitrogen species in RAW264 macrophages. Free Radic Biol Med 2008; 45: 1326-39.
76. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/ reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007; 115: 1408-16.
77. Carnevale R, Pignatelli P, Di Santo S, Bartimoccia S, Sanguigni V, Napoleone L, et al. Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis 2010; 213: 225-34.
78. Hu E. Recent patents on Rho signaling pathway as therapeutic target for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2006; 1: 249-63.
79. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells The role of DDAH. Atherosclerosis 2006.
80. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA, et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 2007; 293: E1703-8.
81. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007; 117: 1718-26.
82. Saarikoski LA, Huupponen RK, Viikari JS, Marniemi J, Juonala M, Kahonen M, et al. Adiponectin is related with carotid artery intimamedia thickness and brachial flow-mediated dilatation in young adults-the Cardiovascular Risk in Young Finns Study. Ann Med 2010; 42: 603-11.
83. Koh EH, Kim M, Ranjan KC, Kim HS, Park HS, Oh KS, et al. ENOS plays a major role in adiponectin synthesis in adipocytes. Am J Physiol Endocrinol Metab 2010; 298: E846-53.
84. Iwata C, Wang X, Uchida K, Nakanishi N, Hattori Y. Buthionine sulfoximine causes endothelium dependent hyper-relaxation and hypoadiponectinemia. Life Sci 2007; 80: 873-8.
85. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: Evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008; 28: 1368-74.
86. Beylot M, Pinteur C, Peroni O. Expression of the adiponectin receptors AdipoR1 and AdipoR2 in lean rats and in obese Zucker rats. Metabolism 2006; 55: 396-401.
87. Bjursell M, Ahnmark A, Bohlooly YM, William-Olsson L, Rhedin M, Peng XR, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 2007; 56: 583-93.
88. Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 2007; 56: 1387-94
89. Zhang P, Wang Y, Fan Y, Tang Z, Wang N. Overexpression of adiponectin receptors potentiates the antiinflammatory action of subeffective dose of globular adiponectin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29: 67-74.
90. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: Effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) 2006; 14: 28-35.
91. Schmid PM, Resch M, Steege A, Fredersdorf-Hahn S, Stoelcker B, Birner C, et al. Globular and Full-Length Adiponectin Induce NODependent Vasodilation in Resistance Arteries of Zucker Lean but Not Zucker Diabetic Fatty Rats. Am J Hypertens 2010.
92. Digby JE, Montague CT, Sewter CP, Sanders L, Wilkison WO, O'Rahilly S, et al. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998; 47: 138-41.
93. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesityrelated inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54: 3358-70.
94. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005; 336: 747-53.
95. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: Effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662-7.
96. Pereira RI, Leitner JW, Erickson C, Draznin B. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase. Life Sci 2008; 83: 638-43.
97. Patel SR, Mailloux LM, Coppola JT, Mindrescu C, Staniloae CS. Pioglitazone increases adiponectin levels in nondiabetic patients with coronary artery disease. Coron Artery Dis 2008; 19: 349-53.
98. Tan GD, Debard C, Funahashi T, Humphreys SM, Matsuzawa Y, Frayn KN, et al. Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 2005; 48: 1585-9.
99. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): Study design and protocol. Diabetologia 2005; 48: 1726-35.
100. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
101. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferatoractivated receptor gamma agonistic activity. J Biol Chem 2005; 280: 23653-9.
102. Nagasaka S, Taniguchi A, Aiso Y, Yatagai T, Nakamura T, Nakai Y, et al. Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes. Diabetes Care 2003; 26: 2215-6.
103. Tsunekawa T, Hayashi T, Suzuki Y, Matsui-Hirai H, Kano H, Fukatsu A, et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 2003; 26: 285-9.
104. Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, et al. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 2005; 52: 427-33.
105. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009; 104: 403-11.
106. Inoue Y, Kakuma T, Nonaka Y, Sumi S, Okamura K, Kodama S, et al. Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels. Clin Exp Hypertens 2010; 32: 21-8.
107. Kamari Y, Shimoni N, Koren F, Peleg E, Sharabi Y, Grossman E. High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rats: the role of the reninangiotensin- aldosterone system. J Hypertens 2010; 28: 95-101.
108. Lely AT, Krikken JA, Bakker SJ, Boomsma F, Dullaart RP, Wolffenbuttel BH, et al. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007; 92: 1821-6.
109. Stenvinkel P. Adiponectin in chronic kidney disease: A complex and context sensitive clinical situation. J Ren Nutr 2011; 21: 82-6.
110. Iwai M, Kanno H, Tomono Y, Inaba S, Senba I, Furuno M, et al. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. J Hypertens 2010; 28: 1471-81.
111. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, et al. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006; 552: 112-22.
112. Yamazaki T, Tanimoto M, Gohda T, Ohara I, Hagiwara S, Murakoshi M, et al. Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice. Nephron Exp Nephrol 2009; 113: e66-76.
113. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
114. Yamada S, Ano N, Toda K, Kitaoka A, Shiono K, Inoue G, et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. Hypertens Res 2008; 31: 601-6.
115. Satoh M, Tabuchi T, Minami Y, Takahashi Y, Itoh T, Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on highmolecular- weight adiponectin concentrations in patients with coronary artery disease. Clin Ther 2009; 31: 2113-25.
116. Yajima K, Shimada A, Hirose H, Oikawa Y, Yamada S, Meguro S, et al. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: A prospective cohort study in primary care. Clin Drug Investig 2009; 29: 811-9.
117. Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J 2009; 73: 1067-73.
118. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-53.
119. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24: 591-6.
120. Mauser W, Perwitz N, Meier B, Fasshauer M, Klein J. Direct adipotropic actions of atorvastatin: Differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 2007; 564: 37-46.
121. Yin X, Tu L, Yang H. Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 248-51.
122. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE. Impact of simvastatin on adipose tissue: Pleiotropic effects in vivo. Endocrinology 2009; 150: 5262-72.
123. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.
124. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649-53.
125. Yokoyama H, Saito S, Daitoku K, Fukuda I, Higuma T, Hanada H, et al. Effects of pravastatin and rosuvastatin on the generation of adiponectin in the visceral adipose tissue in patients with coronary artery disease. Fundam Clin Pharmacol 2010.
126. Bellia A, Rizza S, Galli A, Fabiano R, Donadel G, Lombardo MF, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010; 210: 199-201.
127. Tsutamoto T, Yamaji M, Kawahara C, Nishiyama K, Fujii M, Yamamoto T, et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with nonischaemic chronic heart failure. Eur J Heart Fail 2009; 11: 1195-201.
128. Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity (Silver Spring) 2009; 17: 504-9.
129. Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol 2009; 20: 321-6.
130. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism 2006; 55: 1283-5.
131. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007; 193: 361-5.
132. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536-41.
133. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
134. Shirouchi B, Nagao K, Furuya K, Nagai T, Ichioka K, Tokairin S, et al. Physiological functions of iso-type short-chain fatty acid and omega 3 polyunsaturated fatty acids containing oil in obese OLETF rats. J Oleo Sci 2010; 59: 299-305.
135. Kratz M, Swarbrick MM, Callahan HS, Matthys CC, Havel PJ, Weigle DS. Effect of dietary n-3 polyunsaturated fatty acids on plasma total and high-molecular-weight adiponectin concentrations in overweight to moderately obese men and women. Am J Clin Nutr 2008; 87: 347-53.
136. Sneddon AA, Tsofliou F, Fyfe CL, Matheson I, Jackson DM, Horgan G, et al. Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin. Obesity (Silver Spring) 2008; 16: 1019-24.
137. Shimada M, Mochizuki K, Sakurai N, Goda T. Dietary supplementation with epigallocatechin gallate elevates levels of circulating adiponectin in non-obese type-2 diabetic Goto-Kakizaki rats. Biosci Biotechnol Biochem 2007; 71: 2079-82.
138. Chen TS, Liou SY, Chang YL. Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med 2009; 37: 19-25.
139. Gokbel H, Gergerlioglu HS, Okudan N, Gul I, Buyukbas S, Belviranli M. Effects of coenzyme Q10 supplementation on plasma adiponectin, interleukin-6, and tumor necrosis factor-alpha levels in men. J Med Food 2010; 13: 216-8.
140. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.
141. Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, et al. MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 2009; 119: 2507-15.
142. Shirodaria C, Antoniades C, Lee J, Jackson CE, Robson MD, Francis JM, et al. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. Circulation 2007; 115: 2262-70.
143. Dankner R, Chetrit A, Murad H, Sela BA, Frystyk J, Raz I, et al. Serum adiponectin is associated with homocysteine in elderly men and women, and with 5, 10-methylenetetrahydrofolate reductase (MTHFR) in a sex-dependent manner. Metabolism 2010; 59: 1767-74.
144. Buettner R, Bettermann I, Hechtl C, Gabele E, Hellerbrand C, Scholmerich J, et al. Dietary folic acid activates AMPK and improves insulin resistance and hepatic inflammation in dietary rodent models of the metabolic syndrome. Horm Metab Res 2010; 42: 769-74.
145. Pena AS, Belobrajdic DP, Wiltshire E, Gent R, Hirte C, Couper J. Adiponectin relates to smooth muscle function and folate in obese children. Int J Pediatr Obes 2010; 5: 185-91.
146. Schneider MP, Schlaich MP, Harazny JM, Raff U, Ritt M, Ott C, et al. Folic Acid Treatment Normalizes NOS-Dependence of Vascular Tone in the Metabolic Syndrome. Obesity (Silver Spring) 2010.
147. Wang X, Hattori Y, Satoh H, Iwata C, Banba N, Monden T, et al. Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats. Eur J Pharmacol 2007; 555: 48-53.
148. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, et al. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. J Clin Pharm Ther 2010.
149. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother 2010; 11: 1971-82.
150. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-17.
151. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908-14.
152. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008; 31 (Suppl 2): S229-40.
153. Mitchell PB, Morris MJ. Depression and anxiety with rimonabant. Lancet 2007; 370: 1671-2.
154. Fujii, A., Gabe, T. Adiponectin increasing agent. JP2010189283 (2010).
155. Fujii, A., Hashizume, K. Adiponectin increasing agent. JP2010189291 (2010).
156. Kunieda, Y., Seto, Y. Agent for promoting the secretion and/or suppressing decrease of adiponectin. US2010278794 (2010).
157. Ueda, F. Agent for increasing adiponectin blood quantity. US2010297268 (2010).
158. Morrow, A.L., Martin, L.J., Newburg, D.S. Adiponectin for treatment of various disorders. US20090197806 (2009).
159. Chen, J., Lee, N., Cheng, D. Adiponectin receptor variant, AdipoR2v2. US7598348 (2009).
160. Ranscht, B., Denzel, M. Methods and compositions related to the interaction of T-cadherin and adiponectin. WO2010121207 (2010).
161. Kadowaki, T., Yamauchi, T., Kitajima, S., Ito, Y. Adiponectin expression-inducing agents and uses thereof. US7741080 (2010).
162. Kawamura Y, Tanaka Y, Kawamori R, Maeda S. Overexpression of Kruppel-like factor 7 regulates adipocytokine gene expressions in human adipocytes and inhibits glucose-induced insulin secretion in pancreatic beta-cell line. Mol Endocrinol 2006; 20: 844-56.
163. Zolotukhin, S., Tennant, M.D. Adiponectin gene therapy. US6967018 (2005).